ARGX stock news · argenx
Get alerts for ARGX
Follow argenx (ARGX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ARGXDZ Bank has increased its price goal for argenx to 935 EUR from 861 EUR.
Good for ARGXDZ Bank raised its value estimate for argenx after VYVGART sales exceeded market expectations. This supports a brighter outlook, though the update follows recent quarterly results.
12 health care stocks are changing a lot before the market opens on Thursday.
NeutralThe roundup reports argenx shares fell 15.47% before the market opened. It gives no company news to show a change in the business outlook.
Argenx, Caribou Biosciences, and other major stocks dropped in early trading on Thursday.
Bad for ARGXargenx will stop a late-stage study of efgartigimod for Sjögren’s disease after an interim review found it was unlikely to succeed. That is a setback for the drug’s possible uses.
Value of a $100 investment in argenx from five years ago now stands at $303.45.
NeutralThe article details how a $100 investment in argenx five years ago would be worth $303.45 today, highlighting the company's strong performance relative to the market.
Gold increases by 1%; August sees a rise in the NY Empire State Manufacturing Index.
Good for ARGXShares gained 15% following positive topline results from its Phase 3 ALKIVIA study.
Following the achievement of a significant milestone in its Phase 3 myositis trial, Argenx's stock soars 12%.
Good for ARGXArgenx's stock surged 12% following the announcement of positive results from its Phase 3 trial for efgartigimod, indicating strong potential for the drug in treating autoimmune myositis. The trial's success in meeting its primary endpoint suggests significant clinical benefits, enhancing investor confidence and market valuation.